Fundraising FoxMonograph Capital Partners — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
Evis Hursever(Executive Officer)Wesley McConnell(Executive Officer)inMichael Stella(Executive Officer, Director)William Hawkins(Executive Officer)
BoardMichael Beecham(Director)Andrew Kozlov(Director)
Co-investorsCathay HealthDCVC (Data Collective)4BIO CapitalDigitalis Ventures
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersPfizer Venture InvestmentsSamsara BioCapitalInsight PartnersNewpath Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.